5-MeO-DALT

# Research Output: 5-MeO-DALT

**PSX ID:** PSX-0077  
**Research completed:** 2026-04-26  
**Provenance ID:** 44fa7c42-36ba-4498-ac3d-403e6ccd5e4e

---

## Chemical Identity

**Name:** 5-MeO-DALT (5-methoxy-N,N-diallyltryptamine)  
**Systematic IUPAC name:** N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-N-prop-2-en-1-yl-prop-2-en-1-amine  
**Alternative IUPAC:** N-allyl-N-(2-(5-methoxy-1H-indol-3-yl)ethyl)prop-2-en-1-amine  
**Other names:** Foxtrot (street/market name); N,N-diallyl-5-methoxytryptamine  

**PubChem CID:** 50878551 — verified via API [Ref 16 by proxy; PubChem lookup]  
**Molecular formula:** C₁₇H₂₂N₂O — confirmed [Ref 1, PubChem]  
**Molecular weight:** 270.37 g/mol — confirmed [Ref 1, PubChem]  
**InChIKey:** HGRHWEAUHXYNNP-UHFFFAOYSA-N — confirmed [PubChem]  

**Brief discrepancies:** The brief listed SMILES, molecular formula, molecular weight, InChIKey, and PubChem CID fields as empty. PubChem confirms: formula C₁₇H₂₂N₂O, MW 270.37, CID 50878551, InChIKey HGRHWEAUHXYNNP-UHFFFAOYSA-N. The IUPAC name in the brief matches the PubChem record.

### Physical Properties

**Physical form:** White to off-white (also described as grey, light brown, or tan) crystalline powder; also encountered as yellow, purple, and green compressed tablets [Ref 23].  
**Melting point (freebase):** 105.1°C — from SWGDRUG reference monograph [Ref 26].  
**Melting point (HCl salt):** 160.3°C — from SWGDRUG reference monograph [Ref 26].  
**Solubility:** DMF ~20 mg/mL; DMSO ~15 mg/mL. Freebase is poorly water-soluble; the fumarate salt ("Foxtrot") was specifically developed for water solubility. [Web-retrieved; unverified quantitatively]  
**Predicted boiling point:** ~423°C [web-retrieved, computational prediction]  

**Crystal structure (freebase):** Monoclinic; space group P2₁/n; unit cell a = 6.1444 Å, b = 12.8514 Å, c = 19.3315 Å, β = 91.626°; Z = 4; calculated density 1.177 Mg/m³; colorless plate morphology. Molecules linked by N–H⋯N hydrogen bonds (N⋯N = 2.988 Å) into zigzag chains along [010] (Chadeayne et al. 2020 [Ref 16]).

**Synthesis method:** Speeter–Anthony tryptamine synthesis; a microwave-accelerated version was used in multi-compound reference standard preparations (Brandt et al. 2017 [Ref 11]).

**No stereogenic centers:** 5-MeO-DALT is achiral; stereochemistry not applicable.

---

## Pharmacology

### Receptor Binding Profile

5-MeO-DALT has a complex, multi-target pharmacological profile with no single dominant mechanism. Data are drawn from two key primary sources: Cozzi & Daley (2016) [Ref 2] and Klein et al. (2018) [Ref 1], both of which screened compounds at 45 receptor and transporter sites. More recent functional data come from Kozell et al. (2023) [Ref 12] and Pottie et al. (2019) [Ref 8].

**Binding affinities (Ki):**

| Receptor / Site | Ki (nM) | Source | Notes |
|---|---|---|---|
| 5-HT₁A | 7.95 ± 0.52 | Kozell 2023 [Ref 12] | Full agonist; EC₅₀ ~3.4 nM |
| 5-HT₂A | 48 ± 15 (Kozell) or 250–730 (Cozzi) | [Ref 12] / [Ref 2] | Full agonist; assay discrepancy — see Flags |
| 5-HT₂B | ~10–80 | Cozzi 2016 [Ref 2] | Nanomolar range for 5-substituted DALTs |
| 5-HT₂C | 573 ± 48 | Kozell 2023 [Ref 12] | Full agonist |
| 5-HT₁D | 50–400 | Cozzi 2016 [Ref 2] | Nanomolar range for 5-substituted DALTs |
| 5-HT₆ | 50–400 | Cozzi 2016 [Ref 2] | |
| 5-HT₇ | 50–400 | Cozzi 2016 [Ref 2] | |
| SERT | >1,000 | Kozell 2023 [Ref 12] | Negligible uptake inhibition |
| DAT | Micromolar range | Cozzi 2016 [Ref 2] | Minimal |
| α₂A, α₂B, α₂C adrenergic | Nanomolar–low micromolar | Cozzi 2016 [Ref 2] | |
| σ₁, σ₂ | Micromolar | Cozzi 2016 [Ref 2] | Weak |
| H₁ histamine | Nanomolar | Cozzi 2016 [Ref 2] | Nanomolar for some analogs |
| κ opioid | Present | WHO ECDD 2020 [Ref 23] | Exact Ki not in available abstracts |

**Functional bioassay — 5-HT₂AR β-arrestin2 recruitment:** Pottie et al. (2019) [Ref 8] confirmed 5-MeO-DALT activates 5-HT₂A in a β-arrestin2 recruitment assay with EC₅₀ in the low-micromolar to submicromolar range (precise value in abstract but labeled "micromolar range"; comparable to mescaline in the same assay).

**G-protein activation (rat brain membranes):** Nonaka et al. (2007) [Ref 14] found 5-MeO-DALT the second-most potent tryptamine in a [³⁵S]GTPγS binding assay, ranking: 5-MeO-DMT > 5-MeO-DALT > 5-MeO-AMT > 5-MeO-MiPT > 5-MeO-DiPT > DPT > AMT.

### Mechanism of Action

5-MeO-DALT is primarily a serotonin receptor agonist. Psychedelic-type effects are mediated principally through 5-HT₂A agonism; the concurrent high-affinity 5-HT₁A agonism (Ki ≈ 8 nM) appears to negatively modulate the behavioral expression of 5-HT₂A-mediated effects [Ref 1]. Klein et al. (2018) [Ref 1] demonstrated via multiple regression in the head twitch response (HTR) assay that 5-HT₂A binding makes a significant positive contribution to HTR potency (R² = 0.87 across the DALT series), while 5-HT₁A makes a negative contribution — consistent with 5-HT₁A agonism buffering the psychedelic expression.

The WHO ECDD (2020) [Ref 23] concluded that 5-MeO-DALT has "no clear single mechanism of action," reflecting its broad multi-receptor profile.

### Behavioral Pharmacology (Animal Studies)

**Head Twitch Response (mice):** 5-MeO-DALT produced dose-dependent HTR, confirming hallucinogen-like activity. Within the DALT series, rank order of HTR potency: 4-AcO-DALT > 5-F-DALT > **5-MeO-DALT** > 4-OH-DALT > DALT > 5-Br-DALT. 5-MeO-2-Me-DALT, 5-F-2-Me-DALT, 2-Ph-DALT, and 7-Et-DALT did not induce HTR (Klein et al. 2018 [Ref 1]).

**Drug Discrimination (rats):** 5-MeO-DALT fully substituted for DOM (prototypical hallucinogen; ≥80% drug-appropriate responding), but produced few or no MDMA-like effects in MDMA-trained rats (Gatch et al. 2017 [Ref 9]). This indicates hallucinogen-class discriminative properties without significant entactogen-like character.

**Locomotor activity (mice):** 5-MeO-DALT dose-dependently increased locomotor activity, with peak effect at 10 mg/kg; a higher dose of 25 mg/kg suppressed activity (Gatch et al. 2017 [Ref 9]). This biphasic locomotor pattern is noted as distinct from the locomotor depression seen with NBOMe compounds.

### Pharmacokinetics and Metabolism

**Route-specific bioavailability:** No published human PK studies. Plasma data from a single case report: 7 ng/mL at 8 hours post-ingestion of approximately 10.7 mg oral dose (Dufayet et al. 2022 [Ref 5]). No Tmax, AUC, or bioavailability data published in humans.

**Metabolic pathways (rat model; human liver microsome confirmation):** Michely et al. (2015) [Ref 3] studied metabolic fate in rat urine with pHLM confirmation:
- Phase I: aromatic hydroxylation, aliphatic hydroxylation, N-dealkylation (loss of allyl groups), N-oxidation, O-demethylation (loss of methoxy group → 5-OH-DALT)
- Phase II: glucuronidation and sulfation of Phase I metabolites
- Principal CYP enzymes: **CYP1A2, CYP2C19, CYP2D6, CYP3A4** (Michely 2015 [Ref 3]; consistent with analog data in Caspar et al. 2018 [Ref 15])

**Main urinary detection targets:** N,O-bis-dealkyl metabolite (loss of both allyl groups and methoxy group) and its glucuronide conjugate (Michely 2015 [Ref 3]).

**Detection:** 5-MeO-DALT is NOT detected by standard immunoassay toxicology screens. Confirmed LC-MS/MS detection methods exist and have been validated in blood, urine, and oral fluid [Ref 18, Ref 25]. This is a significant clinical limitation documented in multiple case reports [Ref 5, Ref 6].

---

## History

### Discovery and Synthesis

5-MeO-DALT was first synthesized by Alexander Shulgin, who described synthesis and self-experimental effects in a document sent to a research associate using the pseudonym "Murple" in **May 2004** (Corkery et al. 2012 [Ref 4]; web-retrieved discovery timeline). Shulgin reportedly stated the compound had not previously existed in the scientific literature. A TIHKAL entry for the compound was released online in 2004; however, 5-MeO-DALT was not included in the originally published TiHKAL book.

Synthesis details and self-experiment reports were published by Erowid.org in **August 2004**. The compound became commercially available from internet research chemical vendors around **June 2004**, synthesized by commercial laboratories in China.

The compound first appeared in EMCDDA monitoring reports from **Finland in 2007** and had been reported by **14 European countries** by 2015 (Finland, UK, Belgium, Bulgaria, Germany, Sweden, Hungary, Denmark, France, Croatia, Cyprus, Italy, Norway, and others).

By Shulgin's self-experiments (as cited in Cozzi & Daley 2016 [Ref 2]), 5-MeO-DALT was reported active orally in the **12–20 mg range** with duration of 2–4 hours.

### Analytical Reference Preparation

The Speeter–Anthony synthesis (microwave-accelerated) was used for analytical reference standard preparation of 17 DALTs including 5-MeO-DALT by Brandt et al. (2017) [Ref 11], providing the first comprehensive NMR, GC-MS, LC-MS/MS, and GC-IR spectral reference data for the compound.

---

## Subjective Effects

### Published Descriptions

**Shulgin (self-experiment, as cited Cozzi & Daley 2016 [Ref 2]):** Psychoactive at 12–20 mg oral; reported positive emotional changes, lightheadedness, increased appreciation of music and sex, closed-eye visuals; duration ~2–4 hours.

**Case report data (Jovel et al. 2014 [Ref 6]; Dufayet et al. 2022 [Ref 5]):** Clinical presentations document loss of consciousness, visual hallucinations, extreme agitation, tachycardia, diaphoresis, and combativeness. These are adverse/acute overdose presentations, not descriptions of controlled recreational use.

**User report characterization (web-retrieved; Erowid, PsychonautWiki [Ref 24]):** Anecdotal user reports characterize 5-MeO-DALT effects as predominantly **physical and stimulating** rather than deeply visual or introspective, distinguishing it from classical psychedelics. Euphoria, sensory enhancement, and mild visual alteration are commonly described; profound visual distortions or perceptual depth are reported as less prominent than with DMT or psilocybin. This is consistent with the high 5-HT₁A affinity (which may buffer 5-HT₂A-mediated visuals) and the drug discrimination data showing DOM-like but not MDMA-like character.

**Effect domains documented (from the effects taxonomy in brief, consistent with literature):**
- *Time:* Time alteration
- *Perception:* Tracers, color enhancement/alteration, symmetrical texture repetition, music enhancement, visual acuity enhancement, visual drifting (generally less intense than classical psychedelics)
- *Feeling:* Emotional enhancement
- *Body:* Stimulation (prominent), spontaneous body sensations, sexual arousal enhancement, pupil dilation, temperature dysregulation, wakefulness, abnormal heartbeat
- *Thinking:* Thought connectivity, novelty enhancement, pattern recognition enhancement, conceptual thinking, thought acceleration, analysis enhancement, memory suppression

### Duration Data

From brief seed data (consistent with Shulgin self-experiment as cited [Ref 2] and case report patterns):
- **Oral:** onset 10–15 min; come-up 15–20 min; peak 60–90 min; offset 1–2 hr; total 2–4 hr
- **Smoked:** onset 15–30 sec; come-up 15–30 sec; peak 1–5 min; offset 5–10 min; total 15–20 min; aftereffects 5–10 min

No contradictions between these values and published literature were found. Shulgin's cited data support the 2–4 hr oral duration. Smoked duration data is based on user reports only; no case report data for smoked administration exists in the published literature.

---

## Safety & Toxicity

### Lethal Dose

**No published LD₅₀ data in any species.** Toxic dose in humans is unknown [brief seed data confirmed]. The WHO ECDD (2020) [Ref 23] noted that no formal animal lethal dose studies have been published for 5-MeO-DALT.

### Reported Deaths

Corkery et al. (2012) [Ref 4] reported what they described as **the first death involving 5-MeO-DALT** — a man in his mid-20s who died in **mid-2010** in the United Kingdom. The coroner concluded the deceased "died from injuries sustained after being hit by a lorry whilst under the influence of 5-MeO-DALT." This is an **indirect death** (behavioral intoxication leading to fatal trauma), not direct pharmacological fatality.

No directly drug-caused fatalities (cardiac arrest, respiratory failure, etc.) attributable to 5-MeO-DALT alone have been published as of the literature reviewed.

### Case Reports of Adverse Events

**Case 1 — Delirium (Jovel et al. 2014 [Ref 6]):**  
A previously healthy young male presented to hospital after ingesting a "standard dose" of 5-MeO-DALT. Symptoms: extreme agitation, tachycardia, diaphoresis, combativeness. Required physical restraint and intravenous sedation. Standard toxicology screen negative (5-MeO-DALT not detected). Recovery documented. This was the first published clinical case report.

**Case 2 — Acute Delirium + Rhabdomyolysis (Kalasho & Vibe Nielsen 2016 [Ref 7]):**  
Case report documenting acute delirium plus rhabdomyolysis in a patient using 5-MeO-DALT. Rhabdomyolysis is a life-threatening complication with risk of acute kidney injury; likely mechanism involves hyperthermia and extreme muscular exertion during agitation.

**Case 3 — Cyclic Myoclonus (Thammongkolchai et al. 2015, Neurology conference abstract [Ref 27]):**  
A 29-year-old man (with history of heroin/marijuana use, on buprenorphine) developed markedly reduced oral intake, unresponsiveness, and intermittent myoclonic jerks involving all extremities, trunk, and neck in a cyclic pattern (~every 10 minutes). Brainstem or high spinal cord origin was suspected clinically. IV lorazepam partially effective transiently. EEG showed no ictal/interictal activity; brain MRI unremarkable. Standard urine screen positive only for opioids and cannabinoids. Patient reported 5-MeO-DALT use prior to admission upon recovery; symptoms resolved over one week. **First documented case of myoclonus as a neurological presentation of 5-MeO-DALT.**

**Case 4 — Loss of Consciousness + Visual Hallucinations with Toxicological Confirmation (Dufayet et al. 2022 [Ref 5]):**  
A 46-year-old man consumed 3 tablets of 5-MeO-DALT purchased online; each tablet contained approximately 32.5 mg at 11% purity (≈3.6 mg 5-MeO-DALT per tablet; total ≈10.7 mg). Presented with brief loss of consciousness and visual hallucinations. Plasma concentration: 7 ng/mL at 8 hours post-ingestion (confirmed by LC-MS/MS). This is the first case with quantified plasma levels. Not detected by routine toxicological screening. The extreme impurity (11%) highlights the danger of unregulated online product quality.

### Acute Toxidrome Summary

Across all cases, the documented toxidrome includes: extreme agitation, tachycardia, diaphoresis (sweating), combativeness, visual hallucinations, loss of consciousness, myoclonus, rhabdomyolysis, and encephalopathy. Features overlap with sympathomimetic toxidrome and are consistent with serotonin excess, though full serotonin syndrome triad (altered mental status + neuromuscular abnormalities + autonomic instability) was not formally diagnosed in published cases.

### Organ Toxicity

- **Muscular:** Rhabdomyolysis documented [Ref 7]; risk of acute kidney injury
- **Cardiac:** Tachycardia documented; no published reports of arrhythmia or cardiac arrest
- **Renal:** Risk secondary to rhabdomyolysis; no primary nephrotoxicity documented
- **Neurological:** Myoclonus, encephalopathy, delirium documented

### Psychological Risks

No controlled studies. Acute psychosis, delirium, and agitation documented in case reports. Long-term psychological risks unstudied.

---

## Harm Reduction

### Detection Gap
5-MeO-DALT is **not detected by standard immunoassay toxicology screens** [Ref 5, Ref 6]. Specific LC-MS/MS analysis is required. Clinicians treating suspected intoxication must maintain awareness of this gap. Emergency department physicians should consider synthetic tryptamines when patients present with unexplained sympathomimetic/serotonergic toxidrome and negative routine screens [Ref 10, Ref 5].

### Product Purity
Online products have documented extreme impurity: 11% purity was confirmed analytically in one case (Dufayet 2022 [Ref 5]). This means labeled/nominal doses may be dramatically higher than actual drug content, but conversely, users seeking effects may consume far higher quantities to compensate, creating unpredictable exposure.

### Reagent Testing
No published data on colorimetric reagent test responses for 5-MeO-DALT, but tryptamine compounds generally produce color reactions with Ehrlich's reagent (p-DMAB). This has not been formally validated for 5-MeO-DALT in published literature.

### Clinical Management
Based on case reports: IV benzodiazepines (lorazepam) have been used with partial effect for agitation and myoclonus. IV sedation was required in at least one case [Ref 6]. No specific antidote. Supportive care with monitoring for rhabdomyolysis (creatine kinase, renal function) and hyperthermia is indicated.

### MAO Inhibitor Risk
As a tryptamine, 5-MeO-DALT is expected to carry significant risk of serotonin syndrome when combined with MAO inhibitors (MAOIs). While no 5-MeO-DALT + MAOI case has been published, this risk is well-established for the tryptamine class (structural analogy). The compound's O-demethylation and N-dealkylation by CYP enzymes (and potentially MAO) suggest that MAO inhibition could substantially increase plasma levels and serotonergic activity.

---

## Tolerance & Dependence

### Tolerance
The brief's seed data (buildup: almost immediately after ingestion; half-life: 3 days; full reset: 7 days) is **not confirmed by published substance-specific data**. No human tolerance studies for 5-MeO-DALT have been published.

**Class-level inference:** The mechanism of classical psychedelic tolerance involves 5-HT₂A receptor downregulation with repeated administration. De la Fuente Revenga et al. (2022) [Ref 17] demonstrated in mice that DOI-induced HTR tolerance develops rapidly (within 24h of a single dose), involves 5-HT₂A receptor density reduction in frontal cortex, and shows cross-tolerance between psychedelics (DOI↔LSD) but not with non-psychedelic 5-HT₂A agonists. Given 5-MeO-DALT's 5-HT₂A agonism and HTR activity, rapid tolerance development via this mechanism is expected but not directly confirmed.

**WHO ECDD (2020) [Ref 23]:** Anecdotal reports mentioned tolerance development with daily use. No controlled data.

**Cross-tolerance:** Expected with other classical psychedelics (LSD, psilocybin, mescaline, DMT) based on shared 5-HT₂A mechanism.

### Dependence
No evidence of physical dependence or withdrawal syndrome in published literature. WHO ECDD (2020) [Ref 23]: no validated human abuse liability studies; anecdotal reports do not suggest strong compulsive use. The brief's designation of "not habit-forming" is consistent with the class-level evidence.

---

## Interactions

The brief lists the following known interactions. Evidence assessment for each:

**PCP: lethal**  
⚠️ FLAG — No published case reports or controlled studies documenting a lethal interaction between 5-MeO-DALT and PCP. PCP inhibits reuptake of serotonin, dopamine, and norepinephrine and is an NMDA receptor antagonist. Combined with 5-MeO-DALT's serotonin receptor agonism, the combination could theoretically cause compounded cardiovascular and CNS toxicity. PCP intoxication independently causes hyperthermia, rhabdomyolysis, and behavioral disturbances with fatality risk. The "lethal" designation in the brief is **not confirmed by published evidence for this specific combination**. This value requires editorial review against its original source.

**Tramadol: dangerous**  
**Plausible but unconfirmed substance-specifically.** Tramadol is a serotonin-norepinephrine reuptake inhibitor (SNRI) and weak mu-opioid agonist. Combined with a direct 5-HT₁A and 5-HT₂A agonist such as 5-MeO-DALT, the risk of **serotonin syndrome** is mechanistically significant. No published case reports of this specific combination were found. The "dangerous" rating is pharmacologically reasonable.

**Cocaine: dangerous**  
**Plausible mechanism; unconfirmed substance-specifically.** Cocaine inhibits reuptake of dopamine, serotonin, and norepinephrine. Combined with 5-MeO-DALT's serotonergic agonism, heightened cardiovascular strain (tachycardia, hypertension, hyperthermia) is expected. No published case reports specifically for this combination.

**MDMA: unknown**  
MDMA releases and prevents reuptake of serotonin, dopamine, and norepinephrine. The drug discrimination data (Gatch 2017 [Ref 9]) showed 5-MeO-DALT does not substitute for MDMA in trained rats, suggesting different dominant mechanisms. However, combined serotonergic effects are a plausible concern. Interaction severity unknown.

**Cannabis: unknown**  
No published interaction data.

**Mescaline: unknown**  
No published interaction data. Both are serotonin receptor agonists; potential for pharmacodynamic summation of psychedelic effects.

### Serotonin Syndrome Risk Factors
Based on pharmacology: concurrent use with MAOIs, SSRIs, SNRIs, tramadol, triptans, or other serotonergic substances should be considered high-risk. No controlled data.

### CYP Interactions
5-MeO-DALT is metabolized by CYP1A2, CYP2C19, CYP2D6, and CYP3A4 [Ref 3]. CYP2D6 poor metabolizers may have elevated plasma levels. Inhibitors of CYP2D6 (e.g., fluoxetine, paroxetine, bupropion) or CYP3A4 (e.g., azole antifungals, ritonavir) could reduce clearance and potentiate effects. No clinical data.

---

## Legal Status

| Jurisdiction | Status | Date | Notes |
|---|---|---|---|
| **International (UN 1971 Convention)** | Not scheduled | — | WHO ECDD 43rd meeting (Oct 2020): placed under surveillance; insufficient evidence for international control [Ref 23] |
| **United States (federal)** | Unscheduled | — | Federal Analog Act may apply if used for human consumption as analog of scheduled tryptamines |
| **Florida (US)** | Schedule I | — | State-level controlled |
| **Louisiana (US)** | Schedule I | June 2013 | [Ref 22] |
| **Virginia (US)** | Schedule I | July 1, 2012 | [Ref 22] |
| **United Kingdom** | Class A | January 7, 2015 | Under tryptamine blanket ban [Ref 22] |
| **Sweden** | Controlled | May 1, 2007 | Earliest national control known |
| **China** | Category I psychotropic | September 2010 | [Ref 22] |
| **Japan** | Designated Substance | — | Under Pharmaceutical Affairs Law [Ref 22] |
| **Finland** | Banned | December 2014 | Included in mass-scheduling of 100+ compounds [Ref 22] |
| **Singapore** | Fifth Schedule, MDA | May 2015 | Misuse of Drugs Act [Web-retrieved] |
| **Germany** | Notified to EMCDDA | 2011 | Scheduling status unclear; reported to EMCDDA as an observed NPS |
| **Canada** | Unclear | — | Not explicitly listed in CDSA schedules; may fall under tryptamine analog provisions |
| **Australia** | Unclear | — | No specific scheduling found; status under Poisons Standard unconfirmed |

**EMCDDA reporting history:** First reported by Finland (2007); by 2015, had been reported by 14 EU member states including UK, Belgium, Bulgaria, Germany, Sweden, Hungary, Denmark, France, Croatia, Cyprus, Italy, Norway.

---

## Clinical Trials

**No registered clinical trials found** on ClinicalTrials.gov for 5-MeO-DALT or any of its synonyms. Search confirmed zero results.

This substance has no approved medical use and has not entered any clinical development pipeline.

---

## Community Feedback Analysis

**No community feedback submitted.** The brief's Part A2 section was empty. Standard research directives applied without modification.

---

## Gaps & Flags

### ⚠️ Safety-Critical Flags

1. **PCP interaction labeled "lethal" — unverified.** No published source confirms a lethal interaction between 5-MeO-DALT and PCP specifically. PCP independently causes life-threatening toxicity, and the combination with a serotonergic drug could compound CNS and cardiovascular risk, but the "lethal" designation has no substance-specific evidence base. **Flag for editorial review of source origin.**

2. **LD₅₀ unknown.** No published lethal dose data in any species. The brief's "toxic dose unknown" is confirmed. All dose ranges listed in the brief should be considered unvalidated against controlled safety studies.

3. **Cocaine interaction labeled "dangerous" — not substance-specifically confirmed.** Mechanistic plausibility is high but no published reports specific to 5-MeO-DALT + cocaine exist.

4. **Tramadol interaction "dangerous" — mechanistically plausible but unconfirmed.** Serotonin syndrome risk from combined serotonergic drugs is a real class-level concern but no 5-MeO-DALT + tramadol case has been published.

### ⚠️ Data Discrepancies

5. **5-HT₂A binding affinity discrepancy between sources.** Cozzi & Daley (2016) [Ref 2] reported 5-HT₂A as the weakest 5-HT₂ subtype for the DALT series (Ki 250–730 nM across 5-substituted analogs). Kozell et al. (2023) [Ref 12] / Grokipedia (web-retrieved) report 5-MeO-DALT 5-HT₂A Ki = 48 ± 15 nM. This is a >5-fold discrepancy that may reflect different assay conditions (radioligand, cell system, temperature) or compound-specific values vs. class-range values in Cozzi. The generation agent should use both figures with appropriate caveats; the Kozell 2023 peer-reviewed figure (48 nM) is probably more specifically accurate.

6. **UK scheduling date discrepancy.** Erowid [Ref 22] states Class A since January 7, 2015; Grokipedia (web-retrieved) states June 2014. The Erowid date is the more widely cited and is probably correct; the tryptamine blanket ban came into effect January 2015. Flag if precision is needed.

### Data Gaps

7. **No human pharmacokinetic data.** Only one plasma concentration datapoint from a case report (7 ng/mL at 8h). Tmax, Cmax, AUC, elimination half-life, and bioavailability are unknown.

8. **No smoked administration case reports or controlled data.** Smoked route dose and duration data are based on user reports only.

9. **No published melting point from a peer-reviewed journal.** Melting point data (105.1°C freebase; 160.3°C HCl) comes from the SWGDRUG monograph [Ref 26], which is a technical reference standard rather than a peer-reviewed study.

10. **Australia and Canada legal status unconfirmed.** Could not find definitive scheduling information for either country.

11. **MAOI interaction risk not substance-specifically studied.** Treated as high-risk by class inference only.

12. **No published SMILES from PubChem returned** in this research run (PubChem API returned formula/weight/InChIKey but not SMILES string). SMILES can be obtained directly from PubChem CID 50878551.

13. **Street name variation.** The brief lists "Foxtrot" as the street name. PsychonautWiki appears to use "Foxtrol." Web searches confirm "Foxtrot" is the more common form, associated with the fumarate salt marketed under that name. The brief value ("Foxtrot") appears correct.

14. **Physical property data for smoked route.** No published data on pyrolysis products or smoke composition of 5-MeO-DALT. Safety implications of smoked administration (aside from general risks of inhalation) are unknown.

15. **Thammongkolchai et al. (2015)** was presented as a Neurology conference abstract [Ref 27]. While 43 citations in OpenAlex suggest scientific visibility, its conference abstract status means it should be treated as moderate quality evidence; the findings have not been published in a full peer-reviewed case report.